[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fzILnPSctrR_1lqmj0nAy6s-TW7gXXnI7sD7l1d1FIfc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":36,"rows":43},"RTI International",[4],79,false,20,1,150205,0,75,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"HIV",12,{"name":18,"count":19},"Substance Use",5,{"name":21,"count":22},"Substance Abuse",4,{"name":24,"count":25},"Alcohol Misuse",3,{"name":27,"count":25},"Gender-based Violence",{"name":29,"count":25},"Sexually Transmitted Diseases",{"name":31,"count":32},"Condomless Sex",2,{"name":34,"count":32},"Human Immunodeficiency Virus (HIV)",[],[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,70,93,120,146],{"intervention":45,"totalTrials":9,"cells":46},"RTI-336",{"EARLY_PHASE1":47,"PHASE1":49,"PHASE2":62,"PHASE3":64,"PHASE4":66,"NA":68},{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[51],{"nctId":52,"briefTitle":53,"status":54,"phases":55,"primaryCompletion":56,"completion":56,"start":57,"enrollment":58,"conditions":59,"interventions":61},"NCT00808119","Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects","COMPLETED",[38],"2009-03","2008-10",30,[60],"Cocaine Dependence",[45],{"trials":63,"activeCount":11},[],{"trials":65,"activeCount":11},[],{"trials":67,"activeCount":11},[],{"trials":69,"activeCount":11},[],{"intervention":71,"totalTrials":9,"cells":72},"JDtic",{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":85,"PHASE3":87,"PHASE4":89,"NA":91},{"trials":74,"activeCount":11},[],{"trials":76,"activeCount":11},[77],{"nctId":78,"briefTitle":79,"status":80,"phases":81,"enrollment":82,"conditions":83,"interventions":84},"NCT01431586","First in Humans Study of JDTic","TERMINATED",[38],24,[60],[71],{"trials":86,"activeCount":11},[],{"trials":88,"activeCount":11},[],{"trials":90,"activeCount":11},[],{"trials":92,"activeCount":11},[],{"intervention":94,"totalTrials":9,"cells":95},"Test, Treat, Retain(TTR) only",{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":112,"PHASE3":114,"PHASE4":116,"NA":118},{"trials":97,"activeCount":11},[],{"trials":99,"activeCount":11},[100],{"nctId":101,"briefTitle":102,"status":54,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":111},"NCT01497405","WHC+ (Women's Health CoOp PLUS)",[38],"2015-12","2012-05",641,[15,108,29,21,109,110],"Sexual Risk","Violence","Victimization",[94],{"trials":113,"activeCount":11},[],{"trials":115,"activeCount":11},[],{"trials":117,"activeCount":11},[],{"trials":119,"activeCount":11},[],{"intervention":121,"totalTrials":9,"cells":122},"Ropivacaine",{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":133},{"trials":124,"activeCount":11},[],{"trials":126,"activeCount":11},[],{"trials":128,"activeCount":11},[],{"trials":130,"activeCount":11},[],{"trials":132,"activeCount":11},[],{"trials":134,"activeCount":11},[135],{"nctId":136,"briefTitle":137,"status":54,"phases":138,"primaryCompletion":139,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":144},"NCT03077919","Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness",[42],"2018-06-09","2016-05-25",113,[143],"PostTraumatic Stress Disorder",[121,145],"Sham treatment",{"intervention":145,"totalTrials":9,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":158},{"trials":149,"activeCount":11},[],{"trials":151,"activeCount":11},[],{"trials":153,"activeCount":11},[],{"trials":155,"activeCount":11},[],{"trials":157,"activeCount":11},[],{"trials":159,"activeCount":11},[160],{"nctId":136,"briefTitle":137,"status":54,"phases":161,"primaryCompletion":139,"completion":139,"start":140,"enrollment":141,"conditions":162,"interventions":163},[42],[143],[121,145]]